Israel Englander’s BioMarin Pharmaceuticals BMRN Stock Holding History

Israel Englander’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$1.19M	–	5735
2025 Q4	$1.19M	Buy	20,000 +5,600	+39%	+$305K	﹤0.01%	4367
2025 Q3	$780K	Buy	14,400 +1,100	+8%	+$62.9K	﹤0.01%	4808
2025 Q2	$731K	Buy	13,300 +6,600	+99%	+$389K	﹤0.01%	4645
2025 Q1	$474K	Sell	6,700 -1,600	-19%	-$108K	﹤0.01%	4848
2024 Q4	$546K	Sell	8,300 -60,400	-88%	-$4.05M	﹤0.01%	4681
2024 Q3	$4.83M	Buy	68,700 +55,000	+401%	+$4.6M	﹤0.01%	2876
2024 Q2	$1.13M	Sell	13,700 -17,800	-57%	-$1.48M	﹤0.01%	4018
2024 Q1	$2.75M	Sell	31,500 -31,500	-50%	-$2.82M	﹤0.01%	3454
2023 Q4	$6.07M	Buy	63,000 +38,700	+159%	+$3.42M	﹤0.01%	2621
2023 Q3	$2.15M	Buy	+24,300	New	+$2.16M	﹤0.01%	3487
2023 Q2	–	Sell	-125,300	Closed	-$12.2M	–	6129
2023 Q1	$12.2M	Buy	+125,300	New	+$13M	0.01%	1768
2020 Q3	–	Sell	-15,000	Closed	-$1.85M	–	4459
2020 Q2	$1.85M	Buy	+15,000	New	+$1.49M	﹤0.01%	2598
2014 Q2	–	Sell	-3,900	Closed	-$266K	–	3414
2014 Q1	$266K	Buy	+3,900	New	+$287K	﹤0.01%	3008

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Israel Englander's BMRN Position: Q2 2026 in Review

Israel Englander reduced its BioMarin Pharmaceuticals (BMRN) stake by 31% in Q2 2026, selling an estimated $51.4M and leaving 2,071,816 shares worth $119M. The position accounts for 0.04% of the portfolio, ranked #444.

Israel Englander first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $199M in Q1 2024. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Israel Englander held 2,071,816 shares of BioMarin Pharmaceuticals worth $119M as of Q2 2026.
Israel Englander sold 938,492 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $51.4M.
BioMarin Pharmaceuticals made up 0.04% of Israel Englander's portfolio in Q2 2026, its #444 holding.
Israel Englander first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Israel Englander's BioMarin Pharmaceuticals position peaked at $199M in Q1 2024.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.